CYB003 MDD - Clinical Trial

Still experiencing depression symptoms while taking an antidepressant?

Check Your Eligibility

Adults 18–85 with Major Depressive Disorder may be able to take part in a clinical research study of an investigational medication taken along with their current antidepressant. Study-related care is provided at no cost.

Answer a few questions online to see if you may qualify. Participation is voluntary, and there is no guarantee that you will receive benefit from taking part in this research study.

CYB003 FAQs

About the CYB003 Clinical Trial
  • Trial Name: A study of a Deuterated Psilocin Analog (CYB003) in Humans with Major Depressive Disorder (EMBRACE)
  • Status: Recruiting
  • Condition: Major Depressive Disorder
  • Phase: 3
  • Location: Australia (multiple trial locations nationally)
See If You Qualify
  • Access a clinical research study evaluating an investigational treatment.
  • Continue your current antidepressant therapy during the study.
  • Care is provided by a trained clinical research team.
  • Study-related care is provided at no cost.
  • Participation is voluntary, and there is no guarantee of benefit.
Start Prescreen

Cybin Corp doing business as Helus Pharma is a biotechnology company focused on advancing mental health through next-generation psychedelic-assisted therapies. Our mission is to develop safe and innovative treatments for conditions like Major Depressive Disorder.

CYB003 is part of our commitment to improving outcomes for people who are not fully helped by standard antidepressant treatments.

Check Eligibility
  • Adults 18–85 diagnosed with Major Depressive Disorder.
  • Currently taking an antidepressant for at least 4 weeks, still experiencing symptoms.
  • Able to attend visits at an Australian trial site.
See If You Qualify